# PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

> **NCT05259397** · PHASE1 · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** PF-07225570
- **DRUG:** sasanlimab

## Key facts

- **NCT ID:** NCT05259397
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-03-24
- **Primary completion:** 2022-09-19
- **Final completion:** 2022-09-19
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Pfizer has decided to terminate Study C4661001 due to strategic considerations. This decision is not due to any specific safety reasons or requests from any regulatory authorities. No participants have been enrolled in this study.
- **Last updated:** 2023-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05259397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05259397, "PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05259397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*